Morgan Stanley’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-750
| Closed | -$2.98K | – | 8251 |
|
|
2025
Q3 | $2.98K | Sell |
750
-7,976
| -91% | -$54.3K | ﹤0.01% | 7216 |
|
|
2025
Q2 | $105K | Hold |
8,726
| – | – | ﹤0.01% | 6116 |
|
|
2025
Q1 | $120K | Sell |
8,726
-74
| -0.8% | -$1.06K | ﹤0.01% | 5930 |
|
|
2024
Q4 | $125K | Buy |
8,800
+120
| +1% | +$1.97K | ﹤0.01% | 5971 |
|
|
2024
Q3 | $165K | Sell |
8,680
-1,053
| -11% | -$18K | ﹤0.01% | 5819 |
|
|
2024
Q2 | $190K | Sell |
9,733
-470
| -5% | -$9.08K | ﹤0.01% | 5707 |
|
|
2024
Q1 | $234K | Sell |
10,203
-9,055
| -47% | -$195K | ﹤0.01% | 5680 |
|
|
2023
Q4 | $338K | Buy |
19,258
+8,073
| +72% | +$115K | ﹤0.01% | 5755 |
|
|
2023
Q3 | $146K | Sell |
11,185
-335
| -3% | -$5.07K | ﹤0.01% | 5715 |
|
|
2023
Q2 | $194K | Buy |
11,520
+8,077
| +235% | +$139K | ﹤0.01% | 5659 |
|
|
2023
Q1 | $53.7K | Buy |
3,443
+600
| +21% | +$11.7K | ﹤0.01% | 6260 |
|
|
2022
Q4 | $47.8K | Sell |
2,843
-5,002
| -64% | -$90.1K | ﹤0.01% | 6310 |
|
|
2022
Q3 | $133K | Sell |
7,845
-32,270
| -80% | -$707K | ﹤0.01% | 5930 |
|
|
2022
Q2 | $885K | Sell |
40,115
-36,008
| -47% | -$874K | ﹤0.01% | 5089 |
|
|
2022
Q1 | $2.62M | Sell |
76,123
-30,971
| -29% | -$927K | ﹤0.01% | 4311 |
|
|
2021
Q4 | $4.42M | Buy |
107,094
+53,324
| +99% | +$3.45M | ﹤0.01% | 3850 |
|
|
2021
Q3 | $4.84M | Buy |
53,770
+34,713
| +182% | +$3.06M | ﹤0.01% | 3748 |
|
|
2021
Q2 | $1.39M | Sell |
19,057
-4,853
| -20% | -$226K | ﹤0.01% | 4890 |
|
|
2021
Q1 | $886K | Buy |
23,910
+23,625
| +8,289% | +$1.19M | ﹤0.01% | 4806 |
|
|
2020
Q4 | $12K | Buy |
+285
| New | +$7.39K | ﹤0.01% | 6584 |
|
|
2020
Q3 | – | Sell |
-2,237
| Closed | -$63K | – | 6739 |
|
|
2020
Q2 | $63K | Sell |
2,237
-15,037
| -87% | -$443K | ﹤0.01% | 5598 |
|
|
2020
Q1 | $440K | Buy |
+17,274
| New | +$639K | ﹤0.01% | 4451 |
|
|
2019
Q4 | – | Sell |
-122
| Closed | -$1K | – | 6656 |
|
|
2019
Q3 | $1K | Buy |
122
+120
| +6,000% | +$1.72K | ﹤0.01% | 6535 |
|
|
2019
Q2 | $0 | Sell |
2
-274
| -99% | -$4.89K | ﹤0.01% | 6654 |
|
|
2019
Q1 | $6K | Sell |
276
-3,713
| -93% | -$73.7K | ﹤0.01% | 6288 |
|
|
2018
Q4 | $64K | Sell |
3,989
-6,914
| -63% | -$324K | ﹤0.01% | 5676 |
|
|
2018
Q3 | $1.01M | Buy |
10,903
+6,067
| +125% | +$721K | ﹤0.01% | 4533 |
|
|
2018
Q2 | $776K | Buy |
4,836
+1,216
| +34% | +$205K | ﹤0.01% | 4791 |
|
|
2018
Q1 | $582K | Buy |
3,620
+149
| +4% | +$18.2K | ﹤0.01% | 4912 |
|
|
2017
Q4 | $364K | Buy |
3,471
+363
| +12% | +$39K | ﹤0.01% | 5150 |
|
|
2017
Q3 | $408K | Buy |
3,108
+1,199
| +63% | +$146K | ﹤0.01% | 4999 |
|
|
2017
Q2 | $261K | Buy |
1,909
+346
| +22% | +$41.5K | ﹤0.01% | 5188 |
|
|
2017
Q1 | $186K | Sell |
1,563
-370
| -19% | -$43.7K | ﹤0.01% | 5349 |
|
|
2016
Q4 | $260K | Buy |
+1,933
| New | +$485K | ﹤0.01% | 5240 |
|
|
2016
Q3 | – | Sell |
-110
| Closed | -$12K | – | 6510 |
|
|
2016
Q2 | $12K | Buy |
+110
| New | +$11.5K | ﹤0.01% | 6006 |
|
Other funds holding CLSD
Morgan Stanley's CLSD Position: Q4 2025 in Review
Morgan Stanley sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 750 shares — an estimated $2.98K sold.
Morgan Stanley first reported a position in CLSD in Q2 2016 and held it in 35 quarters. The position peaked at $4.84M in Q3 2021. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- Morgan Stanley reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 750 Clearside Biomedical shares in Q4 2025, an estimated $2.98K.
- Morgan Stanley first reported a position in Clearside Biomedical in Q2 2016 and held it in 35 quarters.
- Morgan Stanley's Clearside Biomedical position peaked at $4.84M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.